Previous study showed that BCL-2 inhibitor Venetoclax and navitoclax enhanced apoptosis in vitro and reduced tumor propagation or burden in BCL-2–expressing lung cancer cells induced animals in vivo [16,17,18]. This evidence concerns the gene BCL2 and neoplasm.